Hemoglobin News and Research RSS Feed - Hemoglobin News and Research

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec Inc. today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013. [More]

New data-based model accurately estimates hemoglobin A1c using SMBG readings

Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. [More]
Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]
Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). [More]

Fewer blood transfusions reduce infection rates by nearly 20%

Blood transfusions are among the most common treatments for hospitalized patients nationwide, but doing them less often reduces infection rates by nearly 20 percent, according to a study in the Journal of the American Medical Association co-authored by Neil Blumberg, M.D., professor at the University of Rochester School of Medicine and Dentistry. [More]

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery. [More]
Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. [More]

NeuroVive Pharmaceutical initiates research collaboration with A1M Pharma

NeuroVive Pharmaceutical AB (publ) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a collaboration agreement signed on 21 March 2014. [More]

Low levels of oxygen, nitric oxide appear to have unfortunate synergy for patients with sickle cell disease

Low levels of both oxygen and the powerful blood vessel dilator nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report. [More]

Aetna honored with 2014 Innovation in Reducing Health Care Disparities Award

Aetna was honored today by the National Business Group on Health (NBGH) with the 2014 Innovation in Reducing Health Care Disparities Award. Aetna is a three-time recipient of the award that recognizes organizations for their commitment to equality in health care and exceptional support for cultural diversity. [More]
Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013. [More]
ADA screening guidelines may lead to missed diagnoses of type 2 diabetes in children, says study

ADA screening guidelines may lead to missed diagnoses of type 2 diabetes in children, says study

New American Diabetes Association (ADA) screening guidelines may lead to the missed diagnoses of type 2 diabetes in children, according to a new study by University of Michigan. [More]
AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities. [More]

Analysis on long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma

An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor. [More]
Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. [More]
Blood pressure lowering linked with reduced risk for cognitive decline in patients with T2DM

Blood pressure lowering linked with reduced risk for cognitive decline in patients with T2DM

Intensive blood pressure and cholesterol lowering was not associated with reduced risk for diabetes-related cognitive decline in older patients with long-standing type 2 diabetes mellitus, according to a study by Jeff D. Williamson, M.D., M.H.S., of the Wake Forest School of Medicine, Winston-Salem, N.C., and colleagues. [More]
Trinidad and Tobago, Johns Hopkins Medicine celebrate achievements of Diabetes Outreach Program

Trinidad and Tobago, Johns Hopkins Medicine celebrate achievements of Diabetes Outreach Program

Members of the Trinidad and Tobago Health Science Initiative’s Diabetes Outreach Program joined the country’s Minister of Health Fuad Khan Tuesday in Port of Spain to celebrate the program’s achievements in fighting diabetes in Trinidad and Tobago. [More]
CCSC identifies 5 routine practices for multidisciplinary teams of critical care professionals

CCSC identifies 5 routine practices for multidisciplinary teams of critical care professionals

The American Association of Critical-Care Nurses (AACN) — as part of the Critical Care Societies Collaborative (CCSC) — has identified five routine critical care practices that should be questioned because they may not always be necessary and could, in fact, be harmful. [More]
Researchers discover simple blood test that can predict diabetes risk much earlier

Researchers discover simple blood test that can predict diabetes risk much earlier

An estimated 25.8 million Americans have diabetes. Another 79 million are thought to have "prediabetes," meaning they are at risk of developing type-2 diabetes. [More]